A step closer to accessing Harvoni as TGA approves use.

A number of sources have today confirmed the Therapeutic Good Administration (TGA) has now approved the use of Harvoni as a prescription medicine in Australia. This is a necessary step before it can be listed on the Pharmaceutical Benefits Scheme (PBS), which the Australian Government is currently considering. 

The Pharmaceutical Benefits Advisory Council (PBAC) recently recommended to the Health Minister, Sussan Ley, that Harvoni (sofosbuvir + ledipasvir) and two other medicines used to treat and cure hepatitis C should be listed on the PBS. Once listed on the PBS the medicines would become affordable for Australians living with hepatitis C. Hepatitis Australia is monitoring developments regarding hepatitis C medicines and will continue to provide updates as information becomes available. 

PBAC will be considering an additional new hepatitis C treatment at its meeting in July. You can find out how to have your say by visiting our New Treatments Page